Bristol/Pfizer's Apixaban Shows Mortality Benefit In ARISTOTLE, But Is It Enough To Supplant Warfarin?
This article was originally published in The Pink Sheet Daily
Executive Summary
New England Journal of Medicine editorial says cost-effectiveness data and head-to-head studies on new oral anticoagulants are needed to move prescribing away from warfarin for atrial fibrillation patients.
You may also be interested in...
Boehringer Will Test How Pradaxa Stacks Up To The Competition In Real-World Study
Global observational study is assessing real-world experience with Pradaxa and other anticoagulants in patients with newly diagnosed atrial fibrillation and at risk of stroke. Results are due in 2020.
Boehringer Will Test How Pradaxa Stacks Up To The Competition In Real-World Study
Global observational study is assessing real-world experience with Pradaxa and other anticoagulants in patients with newly diagnosed atrial fibrillation who are at risk of stroke. Results are due in 2020.
BMS/Pfizer’s Eliquis On Priority Review Path Toward March 2012 Approval
Priority review designation for the Factor Xa inhibitor suggests FDA sees it as a major treatment advance over Pradaxa and Xarelto in reducing the risk of stroke among atrial fibrillation patients.